China's Biotech Sector Secures 31% of New Drug Candidates; U.S. Strengthens Scrutiny Source: Chosun Ilbo, April 14, 2025 Chinese biotech companies are leading the market by securing 31% of global new drug candidates. In response, the U.S. is intensifying its efforts to curb this influence. China's dominance extends to 'super-me-too' drug development and the active pharmaceutical ingredient (API) market. The U.S. is pursuing legislation to restrict the entry of Chinese biotech companies. AI to Replace Animal Testing: Oncocross Gains Attention Following FDA Announcement Source: Seoul Economic Daily, April 14, 2025 The U.S. FDA has announced the gradual phasing out of animal testing in the new drug approval process. Safety verification will be pursued using AI-based predictive models and organoids. Oncocross predicts candidate substances with its AI platform 'Raptor AI'. Its RNA-based 'Oncofind AI' predicts drug responses with 92% accuracy. Oncocross is gaining attention for its potential to enter the global market.